“I don’t think it’d be too much to ask for them to put a little bit of that money into a new facility,” CP3 affiliated faculty Dr. Ben Davies told CNBC about Merck's profits from Keytruda. “They have a financial responsibility to their investors… but I think you have a moral obligation as well.”  Keytruda, a cancer treatment, brought $7 million in revenue for Merck last year.